184 related articles for article (PubMed ID: 23032618)
81. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
[TBL] [Abstract][Full Text] [Related]
82. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors.
Bendell JC; Hong DS; Burris HA; Naing A; Jones SF; Falchook G; Bricmont P; Elekes A; Rock EP; Kurzrock R
Cancer Chemother Pharmacol; 2014 Jul; 74(1):125-30. PubMed ID: 24819685
[TBL] [Abstract][Full Text] [Related]
83. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
84. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Diamond JR; Bastos BR; Hansen RJ; Gustafson DL; Eckhardt SG; Kwak EL; Pandya SS; Fletcher GC; Pitts TM; Kulikowski GN; Morrow M; Arnott J; Bray MR; Sidor C; Messersmith W; Shapiro GI
Clin Cancer Res; 2011 Feb; 17(4):849-60. PubMed ID: 21131552
[TBL] [Abstract][Full Text] [Related]
85. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
86. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
Cohen RB; Jones SF; Aggarwal C; von Mehren M; Cheng J; Spigel DR; Greco FA; Mariani M; Rocchetti M; Ceruti R; Comis S; Laffranchi B; Moll J; Burris HA
Clin Cancer Res; 2009 Nov; 15(21):6694-701. PubMed ID: 19825950
[TBL] [Abstract][Full Text] [Related]
87. A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors.
Traynor AM; Gordon MS; Alberti D; Mendelson DS; Munsey MS; Wilding G; Gammans RE; Read WL
Invest New Drugs; 2010 Aug; 28(4):509-15. PubMed ID: 19434370
[TBL] [Abstract][Full Text] [Related]
88. Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer.
Luyckx M; Votino R; Squifflet JL; Baurain JF
Int J Womens Health; 2014; 6():351-8. PubMed ID: 24729732
[TBL] [Abstract][Full Text] [Related]
89. A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130.
Gelmon KA; Belanger K; Soulieres D; Britten C; Chia S; Charpentier D; Chi K; Powers J; Walsh W; Seymour L
Invest New Drugs; 2005 Oct; 23(5):445-53. PubMed ID: 16133796
[TBL] [Abstract][Full Text] [Related]
90. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.
Joerger M; Stathis A; Metaxas Y; Hess D; Mantiero M; Mark M; Volden M; Kaindl T; Engelhardt M; Larger P; Lane H; Hafner P; Levy N; Stuedeli S; Sessa C; von Moos R
Invest New Drugs; 2020 Aug; 38(4):1067-1076. PubMed ID: 31471863
[TBL] [Abstract][Full Text] [Related]
91. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.
Ramanathan RK; Stephenson JJ; Weiss GJ; Pestano LA; Lowe A; Hiscox A; Leos RA; Martin JC; Kirkpatrick L; Richards DA
Invest New Drugs; 2012 Aug; 30(4):1591-6. PubMed ID: 21863237
[TBL] [Abstract][Full Text] [Related]
92. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.
Annunziata CM; Kohn EC; LoRusso P; Houston ND; Coleman RL; Buzoianu M; Robbie G; Lechleider R
Invest New Drugs; 2013 Feb; 31(1):77-84. PubMed ID: 22370972
[TBL] [Abstract][Full Text] [Related]
93. Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer.
Majhail NS; Hussein M; Olencki TE; Budd GT; Wood L; Elson P; Bukowski RM
Invest New Drugs; 2004 Nov; 22(4):421-6. PubMed ID: 15292712
[TBL] [Abstract][Full Text] [Related]
94. Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.
Isambert N; Fumoleau P; Paul C; Ferrand C; Zanetta S; Bauer J; Ragot K; Lizard G; Jeannin JF; Bardou M
BMC Cancer; 2013 Apr; 13():172. PubMed ID: 23547558
[TBL] [Abstract][Full Text] [Related]
95. A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.
Banerjee S; Michalarea V; Ang JE; Ingles Garces A; Biondo A; Funingana IG; Little M; Ruddle R; Raynaud F; Riisnaes R; Gurel B; Chua S; Tunariu N; Porter JC; Prout T; Parmar M; Zachariou A; Turner A; Jenkins B; McIntosh S; Ainscow E; Minchom A; Lopez J; de Bono J; Jones R; Hall E; Cook N; Basu B; Banerji U
Clin Cancer Res; 2022 Nov; 28(21):4634-4641. PubMed ID: 35984704
[TBL] [Abstract][Full Text] [Related]
96. Trajectory of medication-induced constipation in patients with cancer.
McMillan SC; Tofthagen C; Small B; Karver S; Craig D
Oncol Nurs Forum; 2013 May; 40(3):E92-E100. PubMed ID: 23615153
[TBL] [Abstract][Full Text] [Related]
97. Gynaecological cancer: vintafolide--targeting the folate receptor with a cytotoxic offers hope.
Razzak M
Nat Rev Clin Oncol; 2013 Dec; 10(12):668. PubMed ID: 24165951
[No Abstract] [Full Text] [Related]
98. Labeling Changes for Vinca Alkaloid Chemotherapies.
Aschenbrenner DS
Am J Nurs; 2021 May; 121(5):25. PubMed ID: 33872259
[TBL] [Abstract][Full Text] [Related]
99. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
[TBL] [Abstract][Full Text] [Related]
100. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).
Morris RT; Joyrich RN; Naumann RW; Shah NP; Maurer AH; Strauss HW; Uszler JM; Symanowski JT; Ellis PR; Harb WA
Ann Oncol; 2014 Apr; 25(4):852-858. PubMed ID: 24667717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
